Influenza
Conditions
Brief summary
The purpose of this study is to evaluate the immunogenicity and safety of inactivated subunit H5N1 influenza vaccine in individuals who have previously received live attenuated H2N2, H6N1, or H9N2 influenza vaccine, as well as in individuals who have never previously received H5N1 or other pandemic live attenuated influenza vaccines.
Detailed description
This study will evaluate the immunogenicity and safety of inactivated subunit H5N1 influenza vaccine in individuals who have previously received live attenuated H2N2, H6N1, or H9N2 influenza vaccine, as well as in individuals who have never previously received H5N1 or other pandemic live attenuated influenza vaccines (pLAIVs). Participants will be enrolled in two cohorts. Cohort 1 will include participants who received two doses of live attenuated H2N2, H6N1, or H9N2 influenza vaccine during a prior Center for Immunization Research (CIR) study; Cohort 2 will include participants who have never previously received a pLAIV. Participants in both cohorts will receive one dose of H5N1 pISV vaccine by injection at Day 0. Participants will attend study visits on Days 0, 7, 14, 28, 56, 90, and 360. Study visits may include a physical examination, medical history, and blood and urine collection. All participants will be followed for approximately 360 days after receiving the H5N1 pISV vaccine.
Interventions
BIOLOGICALH5N1 pISV
Administered as an intramuscular (IM) injection
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult males and non-pregnant females between 18 years and 60 years of age inclusive. * General good health, without significant medical illness, physical examination findings, or significant laboratory abnormalities as determined by the investigator. * Available for the duration of the trial. * Able to demonstrate understanding of key study concepts, study rationale, and study participation requirements by scoring greater than or equal to 70% on a written comprehension assessment in 3 or fewer attempts. * Willingness to participate in the study as evidenced by signing the informed consent document. * Willingness to allow storage and testing of laboratory samples for future research. * Received 2 doses of live attenuated H2N2, H6N1, or H9N2 vaccine in a prior trial (Cohort 1) or H2N2, H6N1 and H9N2 naïve (Cohort 2) * Willingness to forego seasonal influenza virus vaccination from 1 month before vaccination until 3 months after vaccination. * Female subjects of childbearing potential must agree to have used effective birth control methods beginning at least one month prior to vaccination, and continuing with 'per label/fully effective use' for the chosen method for duration of the study, from amongst these: * pharmacologic/hormonal contraceptives, including oral, parenteral, subcutaneous, and transcutaneous delivery; * condoms with spermicide; * diaphragm with spermicide; * intrauterine device; * absolute abstinence from heterosexual intercourse as a matter of normal preferred lifestyle; * or must be surgically sterile or must be age 50 AND have had no menses at all for at least one full year. * All females must provide urine for pregnancy testing prior to enrollment (immediately prior vaccination), as well as a statement of menstrual history and a summary of all potentially reproductive sexual activity for the month prior to vaccination, and at each study contact throughout the study, and report known or suspected pregnancy immediately. * Willingness to refrain from blood donation during the course of the study.
Exclusion criteria
* Pregnancy as determined by a positive test for human choriogonadotropin (beta-HCG), an indicator of pregnancy or history of recent unprotected intercourse in a woman of reproductive capacity. * Currently breast-feeding. * Evidence of clinically significant neurologic, cardiac, pulmonary, hematologic, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies. * Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol. * Have medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months. * Other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol. * History of anaphylaxis in response to any vaccine or vaccine component. * History of life-threatening reaction to prior influenza vaccine. * Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory test for human immunodeficiency virus type 1 (HIV-1). * Positive ELISA and confirmatory test (e.g., HCV RNA PCR) for hepatitis C virus (HCV). * Positive hepatitis B virus surface antigen (HBsAg) by ELISA. * Known immunodeficiency syndrome or history suggestive of impaired immune function. * History of Guillain-Barré syndrome. * Use of chronic oral or intravenous administration (greater than or equal to 14 days) of immunosuppressive doses of steroids, i.e., prednisone greater than 10 mg per day, immunosuppressants or other immune-modifying drugs within 30 days of starting this study. * Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study vaccination. * Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination. * Receipt of another investigational vaccine or drug within 30 days prior to study vaccination. * In addition to the above, participants in Cohort 1 (pandemic live attenuated influenza vaccine \[pLAIV\] recipients) and Cohort 2 (naïve cohort) must also not experience any of the following: * Previous enrollment in an H5N1 influenza vaccine trial. * Participants in Cohort 2 (naïve cohort) will be excluded if they are: * Seropositive to the H5N1 influenza A virus (serum hemagglutination inhibition assay (HAI) titer greater than 1:8). * Have previously received an investigational live attenuated influenza vaccine (LAIV) in another study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the Control pLAIV-naïve Cohort | Measured through Day 28 | As measured by enzyme-linked immunosorbent assay (ELISA) and microneutralization assay (MN) using the chimeric cH6/N1 probe |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Measured through Day 28 for non serious adverse events | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: pLAIV Recipients Participants who have received the pandemic live attenuated influenza vaccines (pLAIVs) H2N2, H6N1, or H9N2 during a previous CIR study will receive a single dose of 0.5 mL H5N1 pISV vaccine at Day 0.
H5N1 pISV: Administered as an intramuscular (IM) injection | 11 |
| Cohort 2: pLAIV Naive Participants who have never previously received a pLAIV will receive one dose of 0.5 mL H5N1 pISV vaccine at Day 0.
H5N1 pISV: Administered as an intramuscular (IM) injection | 20 |
| Total | 31 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Taken off study after Day 28 due to unrelated serious adverse event requiring hospitalization | 1 | 0 |
| Overall Study | Volunteer taken off study due to incarceration | 0 | 1 |
Baseline characteristics
| Characteristic | Cohort 1: pLAIV Recipients | Cohort 2: pLAIV Naive | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 11 Participants | 20 Participants | 31 Participants |
| Age, Continuous | 43.7 years | 38 years | 41 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants | 19 Participants | 29 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 12 Participants | 22 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 1 Participants | 5 Participants | 6 Participants |
| Region of Enrollment United States | 11 participants | 20 participants | 31 participants |
| Sex: Female, Male Female | 7 Participants | 6 Participants | 13 Participants |
| Sex: Female, Male Male | 4 Participants | 14 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 11 | 0 / 20 |
| other Total, other adverse events | 8 / 11 | 10 / 20 |
| serious Total, serious adverse events | 1 / 11 | 0 / 20 |
Outcome results
Primary
Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the Control pLAIV-naïve Cohort
As measured by enzyme-linked immunosorbent assay (ELISA) and microneutralization assay (MN) using the chimeric cH6/N1 probe
Time frame: Measured through Day 28
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: pLAIV Recipients | Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the Control pLAIV-naïve Cohort | Day 0 | 1.5 fold rise | Standard Deviation 1.2 |
| Cohort 1: pLAIV Recipients | Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the Control pLAIV-naïve Cohort | Day 28 | 1.4 fold rise | Standard Deviation 1.2 |
| Cohort 2: pLAIV Naive | Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the Control pLAIV-naïve Cohort | Day 0 | 1 fold rise | Standard Deviation 0 |
| Cohort 2: pLAIV Naive | Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the Control pLAIV-naïve Cohort | Day 28 | 1 fold rise | Standard Deviation 0 |
Secondary
Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1, March 2017
Time frame: Measured through Day 28 for non serious adverse events
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: pLAIV Recipients | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Injection site induration | 1 number of participants |
| Cohort 1: pLAIV Recipients | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Malaise | 1 number of participants |
| Cohort 1: pLAIV Recipients | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Injection site pain | 1 number of participants |
| Cohort 1: pLAIV Recipients | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Pain | 1 number of participants |
| Cohort 1: pLAIV Recipients | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Injection site erythema | 0 number of participants |
| Cohort 2: pLAIV Naive | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Pain | 0 number of participants |
| Cohort 2: pLAIV Naive | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Injection site erythema | 1 number of participants |
| Cohort 2: pLAIV Naive | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Injection site induration | 0 number of participants |
| Cohort 2: pLAIV Naive | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Injection site pain | 5 number of participants |
| Cohort 2: pLAIV Naive | Number of Participants With Vaccine-related Adverse Events in the pLAIV Compared to the Control Cohort | Malaise | 1 number of participants |